Siji Zhu1, Yafen Li1, Weiguo Chen1, Xiaochun Fei2, Kunwei Shen1, Xiaosong Chen1. 1. Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 2. Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Abstract
PURPOSE: Breast cancer (BC) patients with T1N0 tumors have relatively favorable clinical outcomes. However, it remains unclear whether molecular subtypes can aide in prognostic prediction for such small, nodal-negative BC cases and guide decision-making about escalating or de-escalating treatments. PATIENTS AND METHODS: T1N0 BC patients diagnosed between 2009 and 2017 were included and classified into three subgroups according to receptor status: 1) hormonal receptor (HR)+/human epidermal growth factor receptor-2 (HER2)-; 2) HER2+; and 3) triple negative (TN) (HR-/HER2-). Patients' characteristics and relapse events were reviewed. Kaplan-Meier analysis and Cox regression were used to assess the iDFS and BCSS. The effects of risk factors and adjuvant treatment benefits were evaluated by calculating hazard ratios (HRs) for invasive disease-free survival (iDFS) and breast cancer-specific survival (BCSS) with Cox proportional hazards models. RESULTS: In total, 2,168 patients (1,435 HR+/HER2-, 427 HER2+, 306 TN) were enrolled. The 5-year iDFS rates were 93.6, 92.7, and 90.6% for HR+/HER2-, HER2+, and TN patients, respectively (P = 0.039). Multivariate analysis demonstrated that molecular subtype (P = 0.043), but not tumor size (P = 0.805), was independently associated with iDFS in T1N0 BC. TN patients [HRs = 1.77, 95% confidence interval (CI) = 1.11-2.84, P = 0.018] had a higher recurrence risk than HR+/HER2- patients. Adjuvant chemotherapy benefit was not demonstrated in all T1N0 patients but interacted with molecular subtype status. TN (adjusted HRs = 2.31, 95% CI = 0.68-7.54) and HER2+ (adjusted HRs = 2.26, 95% CI = 0.95-5.63) patients receiving chemotherapy had superior iDFS rates. Regarding BCSS, molecular subtype tended to be related to outcome (P = 0.053) and associated with chemotherapy benefit (P = 0.005). CONCLUSION: Molecular subtype was more associated with disease outcome and chemotherapy benefit than tumor size in T1N0 BC patients, indicating that it may guide possible clinical de-escalating therapy in T1N0 BC.
PURPOSE: Breast cancer (BC) patients with T1N0 tumors have relatively favorable clinical outcomes. However, it remains unclear whether molecular subtypes can aide in prognostic prediction for such small, nodal-negative BC cases and guide decision-making about escalating or de-escalating treatments. PATIENTS AND METHODS: T1N0 BC patients diagnosed between 2009 and 2017 were included and classified into three subgroups according to receptor status: 1) hormonal receptor (HR)+/human epidermal growth factor receptor-2 (HER2)-; 2) HER2+; and 3) triple negative (TN) (HR-/HER2-). Patients' characteristics and relapse events were reviewed. Kaplan-Meier analysis and Cox regression were used to assess the iDFS and BCSS. The effects of risk factors and adjuvant treatment benefits were evaluated by calculating hazard ratios (HRs) for invasive disease-free survival (iDFS) and breast cancer-specific survival (BCSS) with Cox proportional hazards models. RESULTS: In total, 2,168 patients (1,435 HR+/HER2-, 427 HER2+, 306 TN) were enrolled. The 5-year iDFS rates were 93.6, 92.7, and 90.6% for HR+/HER2-, HER2+, and TN patients, respectively (P = 0.039). Multivariate analysis demonstrated that molecular subtype (P = 0.043), but not tumor size (P = 0.805), was independently associated with iDFS in T1N0 BC. TN patients [HRs = 1.77, 95% confidence interval (CI) = 1.11-2.84, P = 0.018] had a higher recurrence risk than HR+/HER2- patients. Adjuvant chemotherapy benefit was not demonstrated in all T1N0 patients but interacted with molecular subtype status. TN (adjusted HRs = 2.31, 95% CI = 0.68-7.54) and HER2+ (adjusted HRs = 2.26, 95% CI = 0.95-5.63) patients receiving chemotherapy had superior iDFS rates. Regarding BCSS, molecular subtype tended to be related to outcome (P = 0.053) and associated with chemotherapy benefit (P = 0.005). CONCLUSION: Molecular subtype was more associated with disease outcome and chemotherapy benefit than tumor size in T1N0 BC patients, indicating that it may guide possible clinical de-escalating therapy in T1N0 BC.
Authors: Sara M Tolaney; Hao Guo; Sonia Pernas; William T Barry; Deborah A Dillon; Lauren Ritterhouse; Bryan P Schneider; Fei Shen; Kit Fuhrman; Michele Baltay; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Mathew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth Overmoyer; Ann H Partridge; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer Journal: J Clin Oncol Date: 2019-04-02 Impact factor: 44.544
Authors: I Garassino; G Gullo; S Orefice; L Tondulli; G Masci; P Salvini; M Eboli; L Di Tommaso; L Giordano; M Alloisio; M Roncalli; A Santoro Journal: Breast Date: 2009-08-13 Impact factor: 4.380
Authors: Tanja Stüber; Igor Novopashenny; Joachim Diessner; Catharina Bartmann; Roland Stein; Mathias Krockenberger; Sebastian Häusler; Wolfgang Janni; Rolf Kreienberg; Maria Blettner; Achim Wöckel; Manfred Wischnewsky Journal: Oncology Date: 2017-03-24 Impact factor: 2.935
Authors: Yeon Hee Park; Seung Tae Kim; Eun Yoon Cho; Yoon La Choi; Oh-Nam Ok; Hae Jin Baek; Jeong Eon Lee; Seok Jin Nam; Jung-Hyun Yang; Won Park; Doo Ho Choi; Seung Jae Huh; Jin Seok Ahn; Young-Hyuck Im Journal: Breast Cancer Res Treat Date: 2010-02 Impact factor: 4.872
Authors: Otto Metzger Filho; Anita Giobbie-Hurder; Elizabeth Mallon; Barry Gusterson; Giuseppe Viale; Eric P Winer; Beat Thürlimann; Richard D Gelber; Marco Colleoni; Bent Ejlertsen; Marc Debled; Karen N Price; Meredith M Regan; Alan S Coates; Aron Goldhirsch Journal: J Clin Oncol Date: 2015-07-27 Impact factor: 44.544
Authors: Louis Fehrenbacher; Angela M Capra; Charles P Quesenberry; Regan Fulton; Parveen Shiraz; Laurel A Habel Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Sandra M Swain; Gong Tang; Charles E Geyer; Priya Rastogi; James N Atkins; Paul P Donnellan; Louis Fehrenbacher; Catherine A Azar; André Robidoux; Jonathan A Polikoff; Adam M Brufsky; David D Biggs; Edward A Levine; John L Zapas; Louise Provencher; Donald W Northfelt; Soonmyung Paik; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2013-08-12 Impact factor: 44.544
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544